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n daily clinical practice, transcatheter aortic valve replacement (TAVR) is increasingly used in patients at intermediate risk with severe aortic stenosis. [1] [2] [3] [4] [5] [6] [7] [8] The PARTNER II trial (Placement of Aortic Transcatheter Valves Trial II) and the SURTAVI study (Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement) have provided evidence on the safety and efficacy of TAVR in an intermediate-risk population. 9, 10 Such randomized controlled trials, however, are known to cover highly selected patients who do not fully represent real-world populations. For instance, PARTNER II excluded patients with severe comorbidities such as advanced renal impairment or severe ventricular dysfunction. Large prospective registries, including the German Aortic Valve Registry (GARY), are important additional tools that provide information on the short-and longer-term safety and efficacy of a treatment strategy in a real-world population. The purpose of the present study was to compare clinical characteristics and outcomes of an all-comers clinical population at intermediate surgical risk undergoing isolated TAVR or surgical aortic valve replacement (SAVR) for severe aortic stenosis.
METHODS
The data, analytic methods, and study materials will be available to other researchers on request from the authors for purposes of reproducing the results or replicating the procedure.
Registry Design and Ethical Considerations
GARY is a nationwide, prospective, multicenter registry initiated in 2010 to monitor the safety and efficacy of all invasive aortic valve procedures in Germany. The registry is based on an all-comers design with voluntary participation; lack of informed consent by the patient is the only exclusion criterion. Clinical follow-up is obtained at 30 days and 1, 3, and 5 years after the index aortic valve procedure. Initial ethical approval for GARY was obtained from Freiburg University, and patient written informed consent was obtained preprocedurally. The registry design has been previously described in detail. 5, 11, 12 
Study Population
The present study focuses on patients treated with isolated TAVR or SAVR between January 2012 and December 2014. We examined 22.4% (13 182/58 950) of all patients included in the registry who were at intermediate surgical risk as defined by a Society of Thoracic Surgeons (STS) score of 4% to 8%. Of these patients, 64.0% (8437/13 182) were treated by TAVR and 36% (4745/13 182) were treated by SAVR.
Excluded from the present analysis were patients who underwent combined procedures (SAVR and coronary artery bypass grafting: n=13 643 or TAVR and percutaneous coronary intervention: n=383), patients who underwent other combined procedures (such as SAVR and surgical mitral valve repair or TAVR and mitral valve intervention), patients with porcelain aorta, poor prognosis for severe comorbidities, aortic aneurysm, severe left main disease (≥50% stenosis), isolated aortic valve regurgitation, or active endocarditis, patients with cardiopulmonary resuscitation within 48 h prior to the index procedure and patients with any other combined procedure. Thus, from the entire study population of 7613 patients, 6469 who underwent TAVR and 1144 who underwent SAVR were included in this analysis (Figure 1) .
The completeness of follow-up data at 1-year survival was 96.9% (6266/6469) in patients undergoing TAVR and 97.7% (1118/1144) in patients undergoing SAVR. Patients who were event-free at last contact were deemed alive.
Aortic Valve Prosthesis
Patients treated with all licensed TAVR devices and all types of surgical biological aortic valve prostheses were eligible for inclusion in GARY. 
Procedural Characteristics and Clinical End Points
The primary end point was the outcome of patients at intermediate risk treated with TAVR or SAVR in Germany. Furthermore, procedural characteristics and rates of adverse events (eg, myocardial infarction, stroke, acute kidney injury, permanent pacemaker implantation, bleeding or vascular complications, and aortic valve regurgitation ≥ grade II) were analyzed. In this study, all clinical end points were predefined and analyzed according to previous reports.
11

Statistical Analysis
All statistical analyses were performed using the SPSS statistical package version 22.0.0 (IBM Corp). Continuous variables were described using mean and SD. Categorical variables were described using absolute numbers and percentages. Univariate comparisons between patients who underwent SAVR or TAVR were performed using the χ 2 test or Fisher exact test for categorical parameters and the Mann-Whitney U test for continuous variables. Kaplan-Meier curves were derived to assess survival during the 12-month postprocedural period and were compared by log-rank test. Logistic regression analysis was performed to identify clinical variables associated with the performance of TAVR rather than SAVR. All baseline parameters that were significantly associated (P<0.05) with the parameter SAVR/TAVR in univariate analysis were used as independent variables in the model, including age, sex, prior cardiac decompensation, moderate to severe tricuspid valve regurgitation, moderate to severe mitral valve regurgitation, coronary artery disease, New York Heart Association class III/IV, body mass index <22 and >35, prior percutaneous coronary intervention, prior myocardial infarction, prior pacemaker implantation, prior cardioverter-defibrillator implantation, atrial fibrillation, chronic renal impairment, left ventricular ejection fraction <35% and >50%, preprocedural aortic valve area, preprocedural mean aortic pressure gradient, diabetes mellitus, arterial hypertension, neurological 
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dysfunction (central, modified Rankin scale ≥2), prior cardiac surgery, cardiogenic shock, pulmonary hypertension, arterial occlusive disease (symptomatic peripheral arterial occlusive disease, carotid artery disease with stenosis ≥50%, aortic aneurysm >5 cm, or other arterial occlusive disease), and whether or not the procedure was elective. Propensity score analyses were used to reduce confounding in the statistical comparison of 1-year mortality of patients after SAVR and TAVR. The propensity scores were calculated by using the above-mentioned logistic regression model. Resulting propensity scores were used as estimators of the probability of undergoing a TAVR procedure. One-year mortality rates and estimators of the differences between treatment groups were determined for propensity score quintiles. 13 Quintiles were summarized by direct standardization, and stratified estimators describing adjusted mortality rates for patients who underwent SAVI/TAVR were determined. In addition, a propensity score-matched analysis was performed based on the nearest-neighbor approach.
14 Differences were interpreted as being significant for P values <0.05. All P values Values indicate mean±SD or n (%). For a different total n than the totals listed in the column headers, this is indicated by n/total n (%). AV indicates aortic valve; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GARY, German Aortic Valve Registry; NYHA, New York Heart Association; SAVR, surgical aortic valve replacement; s/p, status post; STS, Society of Thoracic Surgeons; and TAVR, transcatheter aortic valve replacement. ORIGINAL RESEARCH ARTICLE were derived from 2-tailed tests. Data management and descriptive parts of the statistical analyses were performed by the BQS Institute for Quality and Patient Safety, Duesseldorf, Germany. The authors had full access to and take full responsibility for the data integrity. All authors have read and agreed to the manuscript as written.
RESULTS
Population of Patients at Intermediate Risk Undergoing TAVR or SAVR in Clinical Practice
Among the study population of 7613 patients, 6469 underwent isolated TAVR (85%) and 1144 underwent isolated SAVR (15%). In 78.9% (5101/6469) of the patients treated by TAVR, a transvascular access was used, whereas a transapical access was used in 21.1% (1368/6469). In the transvascular TAVR group, the majority of patients were treated by using a transfemoral access (98.3%), whereas only a minority of patients (1.7%) were treated by using a different vascular access such as transaortal or transaxillary. Patients treated by either TAVR or SAVR had major differences in baseline characteristics and risk profiles ( Table 1) . The decision to perform TAVR was made by an interdisciplinary heart team in 93.3% of all patients. Documented reasons for performing TAVR in patients at intermediate surgical risk were age (82.5%), frailty (50.8%), patient request (26.2%), and malignant diseases (0.8%) ( Table 2 ). Of all TAVR procedures, 87.3% were elective, and, of all SAVR procedures, 77.2% were elective, with a significantly higher percentage of urgent or emergent procedures in the SAVR group (22.8% versus 12.7%, P<0.001). There were major differences in the proportion of patients with intermediate surgical risk who were treated by TAVR between the 92 sites contributing to the registry, ranging from 36.1% to 100% (Figure 2 ).
In-Hospital Clinical Outcome
In-hospital mortality was 3.6% (41/1144) in patients after TAVR and 3.6% (233/6469) in patients following SAVR (P=0.976) ( Table 3 ). The rate of major stroke during in-hospital course was 1.4% for TAVR versus 1.0% for SAVR (P=0.201). New-onset pacemaker or cardioverter-defibrillator implantation (18.1% versus 4.0%, P<0.001), vascular complications (7.8% versus 0.9%, P<0.001), and aortic valve regurgitation ≥ grade II (4.3% versus 0.5%, P<0.001) were more frequent after TAVR. In contrast, there was a significantly higher rate of postprocedural bleeding with a need for transfusion (22.1% versus 59.6%, P<0.001) or reintervention (1.0% versus 4.7%, P<0.001) and temporary dialysis related to the procedure (1.8% versus 6.5%, P<0.001) among patients who underwent SAVR (Table 3) .
Clinical Outcome at 1-Year Follow-Up
The mortality rate at 1-year follow-up was 17.5% (1131/6469) after TAVR in comparison with 10.8% (123/1144) after SAVR (P<0.001) ( Table 4) . Patients treated by transvascular TAVR had a 1-year mortality rate of 16.5% in comparison with 21.1% in patients treated by the transapical approach (P=0.001). Using product-limit estimations for comparison of all-cause 1-year mortality rates of all TAVR patients (transvascular and transapical) with SAVR ( Figure 3A ) or transvascular TAVR with SAVR ( Figure 3B ), we found a significantly higher mortality rate in patients treated by TAVR than by SAVR (P<0.001) ( Table 4) . Values indicate mean±SD or n (%). For a different total n than the totals listed in the column headers, this is indicated by n/total n (%). SAVR indicates surgical aortic valve replacement; and TAVR, transcatheter aortic valve replacement.
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Multivariable Analysis of Predictors of Performing TAVR Instead of SAVR
Multivariable analysis determined that the following clinical variables were associated with the performance of TAVR instead of SAVR: increased age per year, coronary artery disease, New York Heart Association class III/IV, pulmonary hypertension, prior cardiac decompensation, elective procedure, arterial occlusive disease, no diabetes mellitus, and a smaller aortic valve area before the procedure (P<0.001). In addition, a central neurological dysfunction (modified Rankin scale ≥2, P=0.001), a lower mean aortic pressure gradient before the procedure (P=0.001), mitral valve regurgitation ≥ grade II (P=0.01), atrial fibrillation (P=0.01), and no arterial hypertension (P=0.02) were also associated with TAVR (Table 5) .
Propensity Score Analysis of 1-Year Mortality
Patients were stratified according to their individual propensity score and allocated to quintiles representing their probability of being treated by TAVR instead of SAVR. Quintile 1 represents patients with the lowest probability of undergoing TAVR and consequently the lowest mortality rate. In general, the 1-year mortality rate increased in both treatment groups with increasing probability of undergoing TAVR. In quintiles 1 to 3, reflecting a low to moderate probability of undergoing TAVR instead of SAVR, 1-year mortality was proportionally higher in patients treated by TAVR; however, this difference was only significant in the first quintile (Tables 6 and 7). In contrast, patients with a high probability of undergoing TAVR instead of SAVR (quintiles 4-5) had somewhat higher 1-year mortality rates (P=not significant). After summarizing the propensity scores by using a stratified estimator, we did not detect any significant difference in 1-year mortality between TAVR (transvascular and transapical) and SAVR ( Values indicate mean±SD or n (%). For a different total n than the totals listed in the column headers, this is indicated by n/total n (%). ICD indicates implantable cardioverter-defibrillator; ICU, intensive care unit; RBC, red blood cell; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; and TIA, transient ischemic attack. Values indicate n (%). For a different total n than the totals listed in the column headers, this is indicated by n/total n (%). ICD indicates implantable cardioverter-defibrillator; NYHA, New York Heart Association; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; and TIA, transient ischemic attack.
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at intermediate risk was not published until 2016. Based on our findings, treatment decisions by interdisciplinary heart teams were also based on a multitude of additional clinical factors that are not considered in surgical risk scores but are well known to influence patient outcome. This is in line with current guideline recommendations to consider additional individual and clinical factors that are not reflected in the available risk scores but appreciably influence outcome. 15, 16 Risk scores like the STS score or the EuroSCORE (European System for Cardiac Operative Risk Evaluation) were validated to predict short-term mortality after cardiac surgery in a selected patient population and show notable inaccuracies when transferred to a patient population ORIGINAL RESEARCH ARTICLE undergoing TAVR, in particular over-or underestimation of a patient's actual risk. 6, 8, 17, 18 In the present analysis, 50% of patients treated by TAVR at intermediate surgical risk were classified as frail. Frailty as a clinical condition needs to be characterized precisely, but no scores have been recommended by recent guidelines. Frailty previously was shown to be associated with higher morbidity and mortality rates of patients undergoing cardiac surgery or TAVR. 7, 19 Because frailty was only recorded in patients undergoing TAVR, our propensity model did not include frailty, which possibly biased the results of the propensity analysis against TAVR. The trend toward treating an increasing number of elderly patients at intermediate surgical risk by TAVR in daily practice is in accordance with several previous reports from clinical registries. [1] [2] [3] [4] 9, 10, 20, 21 We observed that GARY showed major differences in the proportion of patients at intermediate risk treated by TAVR between participating sites; our finding was similar to that of a recent analysis from an European Association of Percutaneous Cardiovascular Interventions survey that 45% of 301 interventional centers in Europe performed TAVR in patients at intermediate risk, showing large regional and institutional differences between participating sites.
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Clinical Populations From Randomized Controlled Trials and GARY
The TAVR subpopulation of GARY showed demographic and clinical characteristics that were similar to those of the PARTNER II trial cohort. 23 Patients at intermediate risk in the recently published SURTAVI trial of TAVR with a self-expandable aortic valve prosthesis or 
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SAVR were slightly younger than the patients in GARY and had a lower STS score. 24 Nevertheless, both populations from PARTNER II and SURTAVI who underwent TAVR were the result of a distinct patient selection process, and, consequently, all comparisons of clinical outcome with results from GARY need to be made with caution. Because of major differences with regard to age, surgical risk scores, and baseline characteristics, the surgical subpopulations from PARTNER II and SUR-TAVI are not comparable to the SAVR patient group from GARY.
Clinical Outcome and Major Adverse Events
In our analyses, the unadjusted in-hospital mortality rate was the same (3.6%) for patients treated by TAVR or SAVR, whereas the 1-year mortality rate was 17.5% after TAVR and 10.8% following SAVR. The in-hospital mortality rate in our intermediate-risk TAVR cohort is in accordance with results from the PARTNER II trial, which reported a 30-day mortality rate of 3.9% in their TAVR group; in addition, the STS score of 5.8% and the mean age of 81.5±6.7 years were also comparable to our cohort from GARY (STS score, 5.6%; age, 82.5±5.0 years). 23 The unadjusted 1-year mortality rate among patients undergoing TAVR in GARY was higher (17.5%) than in PARTNER II (12.3%), which is most likely because of a highly selected population in PARTNER II. In patients treated by SAVR, unadjusted data from GARY showed lower rates of in-hospital (3.6%) and 1-year mortality (10.8%) than PARTNER II (30-days, 4.1%; 1-year, 12.9%). This can also be explained by major differences in baseline characteristics and risk profile between the groups. Thus, the results from the 2 SAVR groups cannot be compared. 23 The lower 30-day (2.2%) and 1-year (6.7%) mortality rates in SURTAVI can mainly be explained by a lower STS score and a younger patient population. 24 Unadjusted 1-year mortality was significantly higher in patients after transvascular TAVR than after SAVR in our study. However, product limit estimator analysis showed congruent mortality rates after TAVR and SAVR within the first 60 days after treatment ( Figure 3B ). Not until after 60 days did patients treated by transvascular TAVR have higher mortality rates than those who underwent SAVR ( Figure 3B ). This finding underlines the differences in baseline characteristics between the underlying populations that possibly led to higher mortality in patients treated by TAVR. Consequently, procedure-related differences between TAVR and SAVR do not seem to play an important role in mortality within the first 2 months.
Multivariable Analysis/Propensity Score Analysis
Our data reflect everyday clinical practice and a reasonable selection of patients for TAVR or SAVR by a heart team. As such, the multivariable analysis identified a worse clinical condition and more advanced aortic valve disease as clinical factors associated with performing TAVR rather than SAVR.
To adjust for baseline characteristics and to reduce confounding, we additionally performed a propensity score analysis. No significant differences in 1-year mortality were observed for patients undergoing TAVR and SAVR. In a second step, propensity score matching was performed by comparing the clinical outcomes of 661 patients with similar propensity scores (similar probability of receiving a TAVR). Transvascular TAVR and SAVR were associated with similar 1-year mortality rates (12.8% versus 12.1%, P=0.76) (Figure 4 ), which were similar to all-cause 1-year mortality rates from PARTNER II (TAVR: 12.3% versus SAVR: 12.9%, P=0.69). 23 The SURTAVI trial reported lower all-cause 1-year mortality rates than our results for GARY (TAVR: 6.7% versus SAVR: 6.8%), which might be primarily attributable to differences in risk scores and baseline characteristics. 24 Our results are also in accordance with 3 smaller observational studies using propensity score matching, all of which found no significant differences in 1-year mortality between TAVR and SAVR in an intermediate-risk population. 
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CONCLUSIONS
This analysis of a large, real-world population shows comparable 1-year mortality in patients at intermediate risk treated by TAVR or SAVR. An individualized therapeutic decision by a dedicated heart team based on a patient's clinical situation, relevant comorbidities, and individual procedural risk may currently be the best approach for patients with intermediate surgical risk.
Limitations
There are some limitations to this study. GARY is performed on a voluntary basis for all participating institutions, and for the patients, as well. Therefore, reliable data concerning the completeness of procedures, and the patients, as well, are not available. Nevertheless, we believe that the relatively large number of patients included in this registry from 92 sites is a solid basis for this analysis and enables a realistic survey of invasive aortic valve treatment in patients at intermediate surgical risk in Germany today. The nature of the study is exploratory and the findings need to be interpreted with caution, because confounding factors may have affected the outcome. The TAVR and SAVR populations of GARY differed markedly. Consequently, even the most accurately performed propensity score analysis is not able to compensate for all possible confounders, especially if they are neither detected nor documented. In addition, our propensity score-matched cohort represents ≈18% of the total intermediate-risk population only; the need for exclusion of a majority of patients underlines the difficulty in comparing 2 vastly different patient groups. In our analyses, all patients were stratified retrospectively into different groups of surgical risk according to their STS score, which is supposedly the most reliable score available. All available surgical risk scores, however, are known to be imprecise, especially when applied to a TAVR patient population. 6, [30] [31] [32] The focus on surgical risk scores does not take other important clinical factors (eg, frailty) into account that possibly limit a patient's prognosis. These factors might have influenced the treatment allocation of the heart team and possibly have had a relevant impact on shortand long-term clinical outcome. In GARY, frailty was only recorded in patients treated by TAVR. This represents an important limitation in comparing the 2 treatment groups and possibly biased our propensity model against TAVR. Because of the lack of uniform neurological adjudication in the registry, neurological events are possibly underestimated.
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